Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesRury R. Holman, Adrian F. Hernandez, M. Angelyn Bethel et al.|New England Journal of Medicine|2017Cited by 2.1k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesPierluigi Tricoci, Kenneth W. Mahaffey, Yuliya Lokhnygina et al.|New England Journal of Medicine|2011Cited by 753
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysisM. Angelyn Bethel, Rury R. Holman, Rishi Patel et al.|The Lancet Diabetes & Endocrinology|2017Cited by 591
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationJonathan P. Piccini, Robert M. Califf, Susanna R. Stevens et al.|Circulation|2012Cited by 499
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related OutcomesMarat Fudim, Robert J. Mentz, Jennifer A. White et al.|Circulation|2019Cited by 95